BackRapid Dose Therapeutics Overview
Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics Return on Equity

Rapid Dose Therapeutics (RDTCF) has a ROE of 38.33%, above the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

38.33%

Return on Equity

38.33%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Rapid Dose Therapeutics (RDTCF) FAQ

The latest ROE for RDTCF is 38.33%. That is above the Healthcare sector average of 13.1%. Investors often review this figure alongside Rapid Dose Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, RDTCF currently prints 38.33% for ROE, while the sector average sits near 13.1%. That is roughly 192.5% above the sector mean. Large gaps often invite a closer look at Rapid Dose Therapeutics's growth, margins, and balance sheet.

Return on Equity shows how effectively Rapid Dose Therapeutics converts resources into returns. At 38.33%, RDTCF may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RDTCF's ROE (38.33%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Rapid Dose Therapeutics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.